Drugs / MWN109
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06938269 Comparator | Jun 2025 → Mar 2026 overdue | obesity disorder | Shanghai Minwei Biotechnology Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06859853 Comparator | Mar → Sep 2025 overdue | obesity disorder | Shanghai Minwei Biotechnology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MWN109 | “A Study to Evaluate MWN109 Injection in Healthy Subjects” NCT06859853 ↗ |
| Route | Subcutaneous | “The IP will be administered via SC injection once weekly (QW) for approximately 4 doses.” NCT06859853 ↗ |